Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/148239
Title: Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Author: Vidal Crespo, Anna
Matas Céspedes, Alba
Rodríguez, Vanina
Rossi, Cédric
Valero, Juan G.
Serrat, Neus
Sanjuan Pla, Alejandra
Menéndez Buján, Pablo
Roué, Gaël
López Guillermo, Armando
Giné Soca, Eva
Campo Güerri, Elias
Colomer Pujol, Dolors
Bezombes, Christine
Lammerts van Bueren, J.
Chiu, Christopher
Doshi, Parul
Pérez Galán, Patricia
Keywords: Malaltia de Hodgkin
Limfomes
Cèl·lules B
Hodgkin's disease
Lymphomas
B cells
Issue Date: 11-Jul-2019
Publisher: Ferrata Storti Foundation
Abstract: CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also demonstrated clinical activity in Waldenstrom macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma, as monotherapy or in combination with standard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by Selective Plane Illumination Microscopy that daratumumab fully penetrated a 3D lymphoma organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor outgrowth in models of mantle cell and follicular lymphoma, and shows comparable activity to rituximab in a disseminated in vivo model of blastic mantle cell lymphoma. Moreover, daratumumab improves overall survival in a mouse model of transformed CD20dim follicular lymphoma, where rituximab showed limited activity. Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in mantle cell and follicular lymphoma xenografts. Furthermore, in a patient-derived diffuse large B cell lymphoma xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic opportunity in certain scenarios and these results warrant further clinical development.
Note: Reproducció del document publicat a: https://doi.org/10.3324/haematol.2018.211904
It is part of: Haematologica, 2019
URI: https://hdl.handle.net/2445/148239
Related resource: https://doi.org/10.3324/haematol.2018.211904
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
693580.pdf1.72 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.